Supernus Pharmaceuticals, Inc. (SUPN)
26.16
-0.58
(-2.17%)
USD |
NASDAQ |
Nov 06, 16:00
26.19
+0.03
(+0.11%)
After-Hours: 20:00
Supernus Pharmaceuticals Cash from Operations (Quarterly) : 6.606M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 6.606M |
| June 30, 2026 | -4.81M |
| March 31, 2026 | 66.52M |
| December 31, 2025 | 19.86M |
| September 30, 2025 | -61.66M |
| June 30, 2025 | 58.54M |
| March 31, 2025 | 30.60M |
| December 31, 2024 | 44.41M |
| September 30, 2024 | 53.52M |
| June 30, 2024 | 35.62M |
| March 31, 2024 | 38.40M |
| December 31, 2023 | 44.96M |
| September 30, 2023 | 35.88M |
| June 30, 2023 | -18.87M |
| March 31, 2023 | 49.13M |
| December 31, 2022 | 27.56M |
| September 30, 2022 | 13.84M |
| June 30, 2022 | 71.12M |
| March 31, 2022 | 4.302M |
| December 31, 2021 | 48.76M |
| September 30, 2021 | -4.11M |
| June 30, 2021 | 46.27M |
| March 31, 2021 | 36.20M |
| December 31, 2020 | 31.93M |
| September 30, 2020 | 5.599M |
| Date | Value |
|---|---|
| June 30, 2020 | 91.95M |
| March 31, 2020 | 8.916M |
| December 31, 2019 | 43.79M |
| September 30, 2019 | 37.66M |
| June 30, 2019 | 28.69M |
| March 31, 2019 | 32.99M |
| December 31, 2018 | 32.85M |
| September 30, 2018 | 62.45M |
| June 30, 2018 | 6.556M |
| March 31, 2018 | 27.13M |
| December 31, 2017 | 36.34M |
| September 30, 2017 | 39.00M |
| June 30, 2017 | 25.94M |
| March 31, 2017 | 13.36M |
| December 31, 2016 | 24.94M |
| September 30, 2016 | 28.24M |
| June 30, 2016 | 16.78M |
| March 31, 2016 | -3.142M |
| December 31, 2015 | 22.34M |
| September 30, 2015 | -0.523M |
| June 30, 2015 | 12.98M |
| March 31, 2015 | -0.265M |
| December 31, 2014 | 6.994M |
| September 30, 2014 | 26.78M |
| June 30, 2014 | -6.94M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 56.67M |
| Prestige Consumer Healthcare, Inc. | -- |
| Structure Therapeutics, Inc. | -120.38M |
| Corcept Therapeutics, Inc. | 142.89M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 7.72M |
| Cash from Financing (Quarterly) | -18.40M |
| Free Cash Flow | 86.96M |
| Free Cash Flow Per Share (Quarterly) | 0.1072 |
| Free Cash Flow to Equity (Quarterly) | 10.35M |
| Free Cash Flow to Firm (Quarterly) | 7.037M |
| Free Cash Flow Yield | 5.72% |